Volume 132, Issue 9 pp. 1771-1777
Original Reports

Non-Squamous Cell Malignancies of the Larynx

Janine M. Rotsides MD

Corresponding Author

Janine M. Rotsides MD

Department of Otolaryngology–Head and Neck Surgery, New York University Langone Health, New York, New York, U.S.A.

Send correspondence to Janine M. Rotsides, MD, Department of Otolaryngology–Head and Neck Surgery, NYU Langone Health, 550 1st Ave, NBV-5E5, New York, NY, 10016. E-mail: [email protected]

Search for more papers by this author
Evan Patel MD

Evan Patel MD

Department of Otolaryngology–Head and Neck Surgery, New York University Langone Health, New York, New York, U.S.A.

Search for more papers by this author
Jamie R. Oliver MD

Jamie R. Oliver MD

Department of Otolaryngology–Head and Neck Surgery, New York University Langone Health, New York, New York, U.S.A.

Search for more papers by this author
Lindsey E. Moses MD

Lindsey E. Moses MD

Department of Otolaryngology–Head and Neck Surgery, New York University Langone Health, New York, New York, U.S.A.

Search for more papers by this author
Adam S. Jacobson MD

Adam S. Jacobson MD

Department of Otolaryngology–Head and Neck Surgery, New York University Langone Health, New York, New York, U.S.A.

Search for more papers by this author
Kenneth S. Hu MD

Kenneth S. Hu MD

Department of Radiation Oncology, NYU Langone Health, New York, New York, U.S.A.

Search for more papers by this author
Alec Vaezi MD, PhD

Alec Vaezi MD, PhD

Department of Otolaryngology–Head and Neck Surgery, New York University Langone Health, New York, New York, U.S.A.

Search for more papers by this author
Moses Tam MD

Moses Tam MD

Department of Radiation Oncology, NYU Langone Health, New York, New York, U.S.A.

Search for more papers by this author
Babak Givi MD

Babak Givi MD

Department of Otolaryngology–Head and Neck Surgery, New York University Langone Health, New York, New York, U.S.A.

Search for more papers by this author
First published: 07 January 2022
Citations: 5

Editor's Note: This Manuscript was accepted for publication on December 27, 2021

This abstract was accepted for poster presentation at COSM; AHNS, Austin, TX USA, May 2019.

The authors have no funding, financial relationships, or conflicts of interest to disclose.

Abstract

Objectives/Hypothesis

Non-squamous cell carcinoma (SCC) malignancies are rare, but well described laryngeal pathologies. However, the epidemiology and clinical behavior of these tumors is not well studied.

Study Design

Retrospective cohort study.

Methods

Patients diagnosed with non-squamous cell larynx cancer from 2004 to 2017 in the National Cancer Database were selected. Demographic, clinicopathologic factors, treatments, and survival were analyzed. Univariable and multivariable cox regression were performed. Survival was compared with a propensity score-matched (PSM) population of laryngeal SCC patients.

Results

A total of 136,235 cases of larynx cancer were identified. After excluding SCC variants, 2,172 (1.6%) patients met inclusion criteria. The most common histology was chondrosarcoma (374, 17.2%), followed by small cell (345, 15.9%), and spindle cell carcinoma (268, 12.3%). The most common treatment was surgery (683, 31.4%) followed by chemoradiation (409, 18.8%) and surgery and adjuvant radiation (288, 13.3%). Overall, 3- and 5-year survival was 67.9% and 59.4%, respectively. In multivariate analysis controlling for age, stage, comorbidity, histology, and treatment modality; chondrosarcoma had the best survival (hazard ratio [HR] 0.11, confidence interval [CI] 0.07–0.19, P < .001). In a PSM population, matched for age, stage, comorbidity, and treatments; non-SCC patients had significantly lower survival (51.5% vs. 59.9%, P < .001).

Conclusion

A diverse range of non-squamous cell malignancies occur in the larynx. In general, these tumors have poor survival, with few exceptions such as chondrosarcoma. While the majority of these histologies undergo surgical-based treatments in other sites, only 53% of patients underwent surgical-based treatment in the larynx. These data could guide clinicians in determining the outcome of treatment in these patients.

Level of Evidence

4 Laryngoscope, 132:1771–1777, 2022

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.